Aytu BioPharma reported QQ1 2025 results ending September 30, 2024 that mark a meaningful inflection point in the company’s turnaround. The quarter delivered the first-ever net income from continuing operations and the sixth consecutive quarter of positive adjusted EBITDA, supported by improving traction in both ADHD and Pediatric product lines. ADHD net revenues rose 11% sequentially to $15.3 million, aided by a $3.3 million revenue uplift from the resolution of a multi-year rebate dispute and a return to more normalized gross-to-net dynamics. Pediatric revenue, while down on a year-over-year basis due to prior payer changes, rose 54% sequentially as coverage expansions and targeted promotional investments began to yield payer wins and increased script uptake. The company also completed the wind-down and sale of the Consumer Health business, announced organizational changes designed to reduce operating expenses by at least $2 million annually, and ended the quarter with roughly $20 million in cash. Management emphasized ongoing cost discipline, a lean commercial footprint, and a strategy to de-risk the business through international licensing opportunities and selective in-licensing. While the near-term margin normalization remains affected by legacy inventory costs, management expects a normalized gross margin by early FY2026 and reiterated confidence in generating positive operating cash flow through fiscal 2025. The balance sheet remains solid with a net cash position (net debt of -$3.6 million) and no immediate need for equity financing, supported by a refinanced term loan and deleveraging actions tied to the Grand Prairie wind-down and personnel reductions.